ATRA - Atara Biotherapeutics Inc Stock Price, Fair Value and News

0.69USD+0.03 (+4.55%)Delayed as of 22 Apr 2024, 01:02 pm ET

Market Summary

USD0.69+0.03

Delayedas of 22 Apr 2024, 01:02 pm

4.55%

ATRA Alerts

CITADEL ADVISORS LLC reported owning 6.4% of ATRA [2024-03-18]

ATRA Stock Price

View Fullscreen

ATRA RSI Chart

ATRA Valuation

Market Cap

78.8M

Price/Earnings (Trailing)

-0.29

Price/Sales (Trailing)

114.67

EV/EBITDA

-0.2

Price/Free Cashflow

-0.41

ATRA Price/Sales (Trailing)

ATRA Profitability

EBT Margin

-40190.83%

Return on Equity

278.27%

Return on Assets

-166.84%

Free Cashflow Yield

-246.52%

ATRA Fundamentals

ATRA Revenue

Revenue (TTM)

687.0K

Rev. Growth (Yr)

-52.05%

Rev. Growth (Qtr)

123.41%

ATRA Earnings

Earnings (TTM)

-276.1M

Earnings Growth (Yr)

18.94%

Earnings Growth (Qtr)

13.39%

Breaking Down ATRA Revenue

52 Week Range

0.663.02

(Low)(High)

Last 7 days

-7.0%

Last 30 days

-8.3%

Last 90 days

4.8%

Trailing 12 Months

-76.8%

How does ATRA drawdown profile look like?

ATRA Financial Health

Current Ratio

0.72

ATRA Investor Care

Shares Dilution (1Y)

23.64%

Diluted EPS (TTM)

-2.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	47.9M	32.1M	16.4M	687.0K
2022	24.1M	71.8M	70.9M	63.6M
2021	4.2M	8.0M	13.2M	20.3M
2015	272.0K	412.0K	762.0K	0
2014	40.3K	68.5K	96.8K	125.0K
2013	0	0	0	12.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Atara Biotherapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	fust matthew k	acquired	-	-	150,000	-
Mar 31, 2024	roncarolo maria grazia	acquired	-	-	150,000	-
Mar 31, 2024	mallik ameet	acquired	-	-	150,000	-
Mar 31, 2024	heiden william k	acquired	-	-	150,000	-
Mar 31, 2024	gallagher carol giltner	acquired	-	-	150,000	-
Mar 04, 2024	hyllengren eric j	sold	-4,810	0.720219	-6,679	evp, cfo
Mar 04, 2024	touchon pascal	sold	-17,887	0.72	-24,844	president and ceo
Mar 04, 2024	henrich jill	sold	-2,792	0.72	-3,879	evp, global head ra & quality
Mar 04, 2024	nguyen anhco	sold	-7,737	0.72	-10,746	evp, chief sci. & tech officer
Mar 04, 2024	murugan amar	sold	-7,231	0.72	-10,044	evp, chief legal officer

Which funds bought or sold ATRA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	-	-	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	7.13	25,635	82,621	-%
Apr 05, 2024	CWM, LLC	added	44.94	7,000	14,000	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	30.00	30.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.21	-6,348,180	3,428,600	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	reduced	-71.77	-5,507,030	597,094	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	-46,849	24,687	-%
Feb 26, 2024	Virtu Financial LLC	added	78.97	-6,000	9,000	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	-53,000	29,000	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	new	-	402,000	402,000	0.03%

Are Funds Buying or Selling ATRA?

Are funds buying ATRA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATRA

No. of Funds

ATRA Alerts

CITADEL ADVISORS LLC reported owning 6.4% of ATRA [2024-03-18]

Unveiling Atara Biotherapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 18, 2024	citadel advisors llc	6.4%	6	SC 13G
Feb 14, 2024	maverick capital ltd	0%	0	SC 13G/A
Feb 14, 2024	redmile group, llc	9.9%	10,301,409	SC 13G/A
Feb 13, 2024	vanguard group inc	6.56%	6,686,043	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 06, 2024	goldman sachs group inc	0.6%	580,629	SC 13G/A
Jan 26, 2024	blackrock inc.	7.0%	7,087,213	SC 13G/A
Jan 22, 2024	state street corp	2.73%	2,784,200	SC 13G/A
Jan 09, 2024	baupost group llc/ma	0%	0	SC 13G/A
Dec 07, 2023	jpmorgan chase & co	2.1%	2,206,929	SC 13G/A

Recent SEC filings of Atara Biotherapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	PRE 14A	PRE 14A
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 29, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 18, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Atara Biotherapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Atara Biotherapeutics Inc News

Latest updates

Atara Biotherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3
Revenue	-100.0%	-	2,138,000	957,000	589,000	221,000	4,459,000	51,579,000	7,314,000	7,548,000	5,370,000	3,870,000	3,552,000	380,000	163,000	153,000	66,000	30,000	23,000	6,000	4,500	3,000
Costs and Expenses	-10.5%	64,214,000	71,750,000	-	-	-	89,081,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	72,371,000	76,244,000	75,760,000	89,081,000	83,711,000	95,534,000	100,951,000	90,182,000	87,872,000	81,797,000	-	-	-	-	-	-	-	-	-
S&GA Expenses	-6.5%	11,454,000	12,247,000	13,335,000	13,872,000	13,245,000	18,924,000	18,813,000	20,571,000	21,817,000	19,849,000	19,397,000	17,738,000	-	-	-	-	-	-	-	-	-
R&D Expenses	-12.8%	49,600,000	56,888,000	56,141,000	62,156,000	62,515,000	70,157,000	64,898,000	74,963,000	79,134,000	70,333,000	68,475,000	64,059,000	-	-	-	-	-	-	-	-	-
EBITDA Margin	-2974.5%	-387	-12.59	-8.22	-4.17	-3.50	-3.38	-3.34	-14.15	-16.26	-24.23	-38.78	-71.27	-	-	-	-	-	-	-	-	-
Interest Expenses	-15.7%	1,176,000	1,395,000	1,378,000	1,336,000	117,000	123,000	129,000	4,000	7,000	7,000	8,000	10,000	-	-	-	-	-	-	-	-	-
Income Taxes	157.9%	11,000	-19,000	1,000	22,000	2,000	10,000	-	-	30,000	-	16,000	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	13.4%	-60,439,000	-69,816,000	-71,107,000	-74,749,000	-74,570,000	-84,081,000	18,466,000	-88,105,000	-93,319,000	-84,664,000	-83,777,000	-78,335,000	-	-	-	-	-	-	-	-	-
EBT Margin	-2991.1%	-401	-13.00	-8.44	-4.31	-3.59	-3.48	-3.45	-14.52	-16.72	-24.91	-39.89	-73.31	-	-	-	-	-	-	-	-	-
Net Income	13.4%	-60,450,000	-69,797,000	-71,108,000	-74,771,000	-74,572,000	-84,091,000	18,466,000	-88,105,000	-93,349,000	-84,664,000	-83,793,000	-78,335,000	-	-	-	-	-	-	-	-	-
Net Income Margin	-2991.2%	-401	-13.00	-8.44	-4.31	-3.59	-3.48	-3.45	-14.52	-16.72	-24.91	-39.90	-73.32	-	-	-	-	-	-	-	-	-
Free Cashflow	2.3%	-50,450,000	-51,627,000	-53,295,000	-38,828,000	-56,917,000	-65,189,000	-65,383,000	-87,134,000	-36,735,000	-62,834,000	-63,638,000	-67,895,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.3%	166	189	246	302	376	368	436	397	468	450	457	530	588	406	428	300	343	365	274	325	392
Current Assets	-14.2%	102	119	172	224	295	283	347	314	385	369	392	464	523	339	359	229	273	293	201	251	321
Cash Equivalents	-60.1%	26.00	65.00	46.00	49.00	93.00	66.00	72.00	103	107	115	125	152	202	64.00	76.00	72.00	76.00	96.00	61.00	58.00	62.00
Inventory	47.3%	10.00	7.00	8.00	5.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-16.7%	4.00	5.00	5.00	6.00	6.00	7.00	8.00	9.00	54.00	53.00	51.00	51.00	51.00	52.00	54.00	54.00	54.00	56.00	57.00	58.00	69.00
Liabilities	10.5%	265	240	239	237	250	181	179	173	189	140	125	131	126	52.00	47.00	47.00	52.00	46.00	42.00	41.00	53.00
Current Liabilities	79.8%	142	79.00	75.00	68.00	79.00	72.00	66.00	102	106	86.00	89.00	84.00	83.00	36.00	32.00	32.00	37.00	31.00	26.00	25.00	40.00
Shareholder's Equity	-Infinity%	-99.23	-	7.00	65.00	127	187	257	224	280	310	332	399	462	354	381	253	291	318	232	284	339
Retained Earnings	-3.2%	-1,969	-1,908	-1,838	-1,767	-1,693	-1,618	-1,534	-1,552	-1,464	-1,371	-1,286	-1,202	-1,124	-1,043	-968	-891	-817	-739	-667	-593	-527
Additional Paid-In Capital	0.6%	1,870	1,858	1,847	1,834	1,822	1,809	1,794	1,779	1,745	1,681	1,618	1,602	1,587	1,397	1,349	1,144	1,109	1,058	900	877	867
Shares Outstanding	4.4%	106	102	101	97.00	96.00	102	102	101	92.00	92.00	92.00	91.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	162	-	-	-	715	-	-	-	1,150	-	-	-	907	-	-	-	761	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	1.8%	-50,406	-51,346	-52,796	-38,429	-56,880	-65,057	-63,964	-84,529	-34,269	-58,978	-61,577	-65,698	-4,120	-52,959	-56,636	-67,044	-58,690	-52,147	-54,589	-70,200	-57,419
Share Based Compensation	-10.9%	9,927	11,143	12,552	11,764	11,363	14,023	14,117	14,335	14,028	13,762	13,807	12,268	11,504	13,255	13,948	12,644	12,074	12,152	15,201	12,269	9,553
Cashflow From Investing	-85.9%	9,944	70,447	49,482	-6,007	51,218	59,697	31,826	60,215	-24,324	1,194	31,889	13,499	-36,892	7,562	-130,371	38,973	1,127	-58,517	50,253	67,596	46,068
Cashflow From Financing	826.9%	1,512	-208	471	235	32,290	-214	1,157	19,851	51,468	47,137	2,447	2,892	178,796	33,506	191,315	23,957	37,449	145,936	7,327	-1,926	6,021

ATRA Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Commercialization revenue	$ 7,886	$ 0
License and collaboration revenue	687	63,573
Revenue from Contract with Customer, Including Assessed Tax, Total	8,573	63,573
Costs and operating expenses:
Cost of commercialization revenue	8,886	0
Research and development expenses	224,785	272,533
General and administrative expenses	50,908	71,553
Total costs and operating expenses	284,579	344,086
Loss from operations	(276,006)	(280,513)
Other income (expense), net:
Interest income	5,426	3,059
Interest expense	(5,285)	(373)
Gain on sale of ATOM Facility (See Note 7)	0	50,237
Other income (expense), net:	(246)	(700)
Total other income (expense), net	(105)	52,223
Loss before provision for income taxes	(276,111)	(228,290)
Provision for income taxes	15	12
Net loss	(276,126)	(228,302)
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities	1,863	(1,699)
Comprehensive loss	$ (274,263)	$ (230,001)
Net loss per common share:
Basic net loss per common share	$ (2.61)	$ (2.24)
Diluted net loss per common share	$ (2.61)	$ (2.24)
Basic weighted-average shares outstanding	105,912	101,990
Diluted weighted-average shares outstanding	105,912	101,990

ATRA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 25,841	$ 92,942
Short-term investments	25,884	149,877
Restricted cash	146	146
Accounts receivable	34,108	40,221
Inventories	9,706	1,586
Other current assets	6,184	10,308
Total current assets	101,869	295,080
Property and equipment, net	3,856	6,300
Operating lease assets	54,935	68,022
Other assets	4,844	7,018
Total assets	165,504	376,420
Current liabilities:
Accounts payable	3,684	6,871
Accrued compensation	11,519	17,659
Accrued research and development expenses	17,364	24,992
Deferred revenue	77,833	8,000
Other current liabilities	31,826	21,394
Total current liabilities	142,226	78,916
Deferred revenue - long-term	37,562	77,000
Operating lease liabilities - long-term	45,693	58,064
Liability related to the sale of future revenues - long-term	34,623	30,236
Other long-term liabilities	4,631	5,564
Total liabilities	264,735	249,780
Commitments and contingencies (Note 10)
Stockholders' equity (deficit):
Common stock-$0.0001 par value, 500,000 shares authorized as of December 31, 2023 and 2022, respectively; 106,447 and 95,927 shares issued and outstanding as of December 31, 2023 and 2022, respectively	11	10
Additional paid-in capital	1,870,112	1,821,721
Accumulated other comprehensive (loss) income	(204)	(2,067)
Accumulated deficit	(1,969,150)	(1,693,024)
Total stockholders' equity (deficit)	(99,231)	126,640
Total liabilities and stockholders' equity (deficit)	$ 165,504	$ 376,420

About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

CEO	Dr. Pascal Touchon D.V.M.
WEBSITE	atarabio.com
INDUSTRY	Biotechnology
EMPLOYEES	317

Atara Biotherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Atara Biotherapeutics Inc? What does ATRA stand for in stocks?

ATRA is the stock ticker symbol of Atara Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Atara Biotherapeutics Inc (ATRA)?

As of Fri Apr 19 2024, market cap of Atara Biotherapeutics Inc is 78.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATRA stock?

You can check ATRA's fair value in chart for subscribers.

What is the fair value of ATRA stock?

You can check ATRA's fair value in chart for subscribers. The fair value of Atara Biotherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Atara Biotherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Atara Biotherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ATRA is over valued or under valued. Whether Atara Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Atara Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATRA.

What is Atara Biotherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, ATRA's PE ratio (Price to Earnings) is -0.29 and Price to Sales (PS) ratio is 114.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATRA PE ratio will change depending on the future growth rate expectations of investors.